Comparative Pharmacology
Head-to-head clinical analysis: PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE versus THORAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE versus THORAZINE.
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE vs THORAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Perphenazine is a phenothiazine antipsychotic that blocks postsynaptic dopamine D2 receptors in the mesolimbic system, with additional antagonism at serotonin 5-HT2, alpha-1 adrenergic, histamine H1, and muscarinic M1 receptors. Amitriptyline is a tricyclic antidepressant that inhibits serotonin and norepinephrine reuptake, also antagonizing histamine H1, alpha-1 adrenergic, and muscarinic M1 receptors.
Antagonist at dopamine D2 receptors in the mesolimbic pathway; also blocks alpha-adrenergic, histaminergic, and muscarinic receptors.
Oral: Perphenazine 2-4 mg with amitriptyline 10-50 mg, administered 3-4 times daily. Maximum daily dose: perphenazine 24 mg, amitriptyline 150 mg.
10-25 mg orally 3-4 times daily; maximum 800 mg/day. 25-50 mg intramuscularly every 4-6 hours.
None Documented
None Documented
Perphenazine: ~9-12 hours (range 8-20 h). Amitriptyline: ~15-24 hours (range 10-50 h). Clinical context: Steady-state reached in 3-10 days; amitriptyline's active metabolite nortriptyline has T½ ~18-35 h.
Terminal elimination half-life: 15–30 hours (mean ~24 h); may extend to 40+ h in elderly or hepatic impairment.
Perphenazine: renal (0.5-2% unchanged), hepatic metabolism and biliary/fecal elimination (major). Amitriptyline: renal (<5% unchanged, 30-50% as metabolites), biliary/fecal (significant). Combined: ~70-80% renal (metabolites), ~20-30% fecal.
Renal (biliary/fecal): ~70% renal as metabolites, ~30% biliary/fecal; <1% unchanged in urine.
Category A/B
Category C
Typical Antipsychotic
Typical Antipsychotic